Around the Practice June 23, 2021: Genomic and Genetic Testing in Prostate Cancer

This installment of Around the Practice focused on genomic testing in prostate cancer.

EP1: Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer

June 29th 2021

Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.

EP2: Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer

June 29th 2021

Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care.

EP3: Dr. Helfand on the increasing role of genomic testing in prostate cancer

July 27th 2021

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, explains the increased significance of genomic testing in the field of prostate cancer.

EP4: How genomic testing can address accuracy issues with PSA screening and monitoring

July 27th 2021

Brian T. Helfand, MD, PhD, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.

EP5: Dr. Helfand on how genomic testing provides real-time status of prostate tumor

July 29th 2021

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

EP6: Complementary use of mpMRI and genomic testing in prostate cancer

August 3rd 2021

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.